Gut Microbiota-Directed Interventions in Type 2 Diabetes: A Systematic Review of Clinical Outcomes and Complication Risk
Abstract
Type 2 diabetes mellitus is increasingly recognized as a disorder not only of glucose metabolism but also of gut microbial imbalance, with emerging evidence suggesting a bidirectional link between microbiome composition and metabolic dysfunction. Recent randomized controlled trials and dietary interventions highlight that specific microbial taxa, such as butyrate-producing bacteria and Akkermansia muciniphila, play crucial roles in regulating insulin sensitivity, lipid metabolism, and systemic inflammation. Modulation of the gut-metabolic axis through probiotics, prebiotics, dietary strategies, and pharmacological agents demonstrates promising effects on glycemic control, cardiometabolic risk reduction, and attenuation of diabetes-related complications, though results vary across populations and intervention types. The variability in outcomes underscores the importance of personalized approaches, where baseline microbiota signatures may dictate therapeutic response. Despite encouraging findings, many studies remain limited by short duration, small sample size, and heterogeneity in microbiome analysis methods. This review synthesizes current evidence, highlights mechanistic insights linking microbial shifts to metabolic benefits, and identifies gaps in the literature. By doing so, it emphasizes the potential of microbiome-directed therapies as adjunctive strategies in the prevention and management of type 2 diabetes and its complications.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.